CHICAGO (MedPage Today) -- Adding a growth factor to the immune-stimulating drug ipilimumab significantly improved overall survival (OS) in patients with metastatic melanoma, a proof-of-principal phase II study showed. via MedPageToday.com - medical news plus CME for physicians Read More Here..
No comments:
Post a Comment